As Nigeria joined the global community to commemorate World Hepatitis Day recently with the theme “Hepatitis: Let’s Break It Down,” the reality confronting the nation could not be more urgent. With over 20 million Nigerians living with Hepatitis B and C—18.2 million affected by Hepatitis B and 2.5 million by Hepatitis C—Nigeria carries the unwelcome distinction of having the third-highest hepatitis burden globally.
In the considered opinion of this newspaper,this is a national emergency that demands immediate, comprehensive action.
The theme for this year’s commemoration calls for dismantling the financial, social, and systemic barriers that prevent millions from accessing life-saving care. Yet, as the Coordinating Minister of Health and Social Welfare , Ali Pate outlined the government’s ambitious plans, including the launch of “Project 365” and the establishment of a Viral Elimination Fund, one fundamental question emerges: Will this administration finally translate promises into tangible results where previous governments have failed?
The numbers paint a devastating picture of institutional neglect and systemic failure. Over 8.1% of Nigeria’s population is infected with Hepatitis B, yet more than 90% of those infected remain undiagnosed.
These individuals unknowingly transmit the virus to others, including innocent children, perpetuating a cycle of infection that has persisted for decades.
The tragedy is compounded by frequent misdiagnosis, with symptoms such as fever, fatigue, and malaise routinely treated as malaria while the virus silently destroys liver function, potentially progressing to liver failure or cancer.
The human cost is staggering: 4,252 Nigerians die annually from liver cancer caused by untreated hepatitis. Behind each statistic is a family devastated, a breadwinner lost, and a community weakened.
The economic implications are equally catastrophic, with Nigeria losing between ₦13.3 trillion and ₦17.9 trillion annually in direct and indirect costs. This represents resources that could have been channeled into national development, education, infrastructure, and poverty alleviation.
What makes this crisis particularly inexcusable is that both Hepatitis B and C are preventable, treatable, and in the case of Hepatitis C, completely curable. The vaccines exist. The treatments work. The diagnostic tools are available. Yet Nigeria continues to lag behind in implementation, allowing a preventable epidemic to ravage its population while countries with far fewer resources make significant strides in hepatitis elimination.
The government’s announcement of “Project 365” represents the latest in a series of well-intentioned initiatives.
However, given Nigeria’s track record of launching programs with great fanfare only to see them falter due to poor implementation, inadequate funding, or bureaucratic inefficiency, skepticism is justified.
The establishment of the Viral Elimination Fund and promises of increased budgetary support sound promising, but Nigerians have heard similar commitments before.
In our view, what is needed now is not more rhetoric but demonstrable commitment backed by concrete action. The success of any hepatitis elimination program hinges on several critical factors that the government must address with unprecedented seriousness.
First, healthcare infrastructure at the primary level must be strengthened to ensure that screening and treatment services reach rural and underserved communities where the burden is often highest. Second, healthcare workers require intensive training to improve diagnostic accuracy and reduce the endemic misdiagnosis that allows hepatitis to masquerade as malaria.
Third, public awareness campaigns must be sustained and culturally appropriate, addressing the stigma that prevents many Nigerians from seeking testing and treatment. The silence surrounding hepatitis, often due to misconceptions about transmission and curability, contributes significantly to the spread of infection.
Community leaders, religious organisations, and traditional rulers must be mobilised as partners in this awareness drive.
Fourth, the pharmaceutical supply chain must be reliable and affordable. The government’s emphasis on local manufacturing is commendable, but this must be accompanied by quality assurance measures to ensure that locally produced medications meet international standards.
Tax incentives and regulatory reforms are positive steps, but they must be implemented transparently and monitored rigorously.
The integration of hepatitis services into existing healthcare programs, particularly those targeting HIV and other sexually transmitted infections, offers a practical pathway to scaling up interventions.
However, this requires coordination across multiple agencies and levels of government—an area where Nigeria has historically struggled.
State governments cannot be mere spectators in this fight.
Hepatitis affects all regions of the country, and state-level commitment to funding, policy implementation, and service delivery is crucial. The federal government’s initiatives will fail without robust support from state and local government areas.
Furthermore, the National Assembly must fulfill its legislative responsibilities by ensuring adequate budgetary allocations and oversight of program implementation. Too often, health initiatives suffer from inconsistent funding and poor monitoring, leading to program failures that cost lives.
The private sector, including pharmaceutical companies, diagnostic laboratories, and healthcare providers, must also be genuine partners rather than mere profit-seekers. Corporate social responsibility in health should extend beyond token gestures to meaningful contributions to hepatitis elimination efforts.
Pointedly,the government’s promise to eliminate Hepatitis C and halt Hepatitis B transmission by 2030 is ambitious but achievable—if matched with unwavering political will, adequate resources, and effective implementation. The question is not whether Nigeria has the capacity to win this fight, but whether it has the determination to see it through.
